20582-55-2

Usage

Chemical Properties

white to light yellow crystal powde

InChI:InChI=1/C8H11NO4S/c1-3-13-7(10)6-5(2)4-14-9(6)8(11)12/h4,6H,3H2,1-2H3,(H,11,12)

Upstream product

• 115-08-2 thiocarboxamide 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 77287-34-4 formamide 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 17309-13-6 ethyl 2-mercapto-4-methyl-5-thiazolecarboxylate 
• 52481-66-0 ethyl 2-hydrazinyl-4-methylthiazole-5-carboxylate 
• 64-17-5 ethanol 
• 7647-01-0 hydrogenchloride 
• 7722-84-1 dihydrogen peroxide 
• 7210-76-6 ethyl-2-amino-4-methylthiazole-5-carboxylate 
• 17309-13-6 ethyl 4-methyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carboxylate 

Downstream Products

• 102787-95-1 5-ethoxycarbonyl-3-(4-amino-2-methyl-pyrimidin-5-ylmethyl)-4-methyl-thiazolium; chloride-hydrochloride 
• 760203-29-0 4-methyl-thiazole-5-carboxylic acid amide 
• 20485-41-0 4-methylthiazole-5-carboxylic acid 
• 1977-06-6 (4-methyl-1,3-thiazol-5-yl)methanol 
• 129201-13-4 4-Chloro-benzoic acid 4-methyl-thiazol-5-ylmethyl ester 
• 78502-77-9 4-Brommethyl-5-thiazolcarbonsaeure-ethylester 
• 78502-78-0 4-Dibrommethyl-5-thiazolcarbonsaeure-ethylester 
• 82294-70-0 4-methyl-1,3-thiazole-5-carbaldehyde 
• 50382-33-7 (4-methyl-1,3-thiazol-5-yl)acetonitrile 
• 1096156-23-8 ethyl 2-acetyl-4-methylthiazole-5-carboxylate 

Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel thiazole-derivatives as mitochondrial targeting inhibitors of cancer cells

Mitochondria are pivotal energy production sources for cells to maintain necessary metabolism activities. Targeting dysfunctional mitochondrial features has been a hotspot for mitochondrial-related disease researches. Investigation with cancerous mitochondrial metabolism is a continuing concern within tumor therapy. Herein, we set out to assess the anti-cancer activities of a novel family of TPP-thiazole derivatives based on our earlier research on mitochondrial targeting agents. Specifically, we designed and synthesized a series of TPP-thiazole derivatives and revealed by the MTT assay that most synthesized compounds effectively inhibited three cancer cell lines (HeLa, PC3 and MCF-7). After structure modifications, we explored the SAR relationships and identified the most promising compound R13 (IC50 of 5.52 μM) for further investigation. In the meantime, we performed ATP production assay to assess the selected compounds inhibitory effect on HeLa cells energy production. The results displayed the test compounds significantly restrained ATP production of cancer cells. Overall, we have designed and synthesized a series of compounds which exhibited significant cytotoxicity against cancer cells and effectively inhibited mitochondrial energy production.

Iron-catalyzed tandem oxidative coupling and acetal hydrolysis reaction to prepare formylated benzothiazoles and isoquinolines

The aldehyde group is one of the most versatile intermediates in synthetic chemistry, and the introduction of an aldehyde group into heteroarenes is important for the transformation of molecular structure. Herein, we achieved the direct formylation of benzothiazo/les and isoquinolines. The reaction features a novel iron-catalyzed Minisci-type oxidative coupling process using commercially available 1,3-dioxolane as a formylated reagent followed by acetal hydrolysis without a separation process. The reaction can be performed under exceedingly mild reaction conditions and exhibits broad functional group tolerance.

Method for preparing 4-methylthiazole-5-ethyl formate

The invention discloses a preparation method of 4-methylthiazole-5-ethyl formate. The preparation method comprises the following steps: taking tetrahydrofuran as a solvent and formamide and phosphorus sulfide as raw materials, dissolving the phosphorus sulfide in the tetrahydrofuran firstly, dropwise adding the formamide, carrying out reaction for 1-2h, concentrating to dry, dissolving a dried product with a low-concentration sodium hydroxide solution, carrying out extraction with ethyl acetate, drying an organic layer, and filtering and concentrating to obtain thioformamide; and taking absolute ethyl alcohol as a solvent and the thioformamide and 2-chloracetyl acetidin as raw materials, carrying out reflux reaction, concentrating a reactant to dry, dissolving the dried reactant with water, extracting with the ethyl acetate, drying an organic layer, filtering, concentrating and carrying out rectification under vacuum to obtain the 4-methylthiazole-5-ethyl formate. The preparation method provided by the invention is low in cost and convenient to operate.

Process for Preparing Ethyl-4-methyl-5-thiazolecarboxyate

Provided is a method for preparing ethyl-4-methyl-5-thiazolecarboxylate, used as an intermediate for manufacturing Febuxostat, an arthrifuge, in an efficient and economical manner and environmentally friendly conditions. The method comprises the following steps: (i) reacting ethyl 2-chloroacetoacetate and ammonium dithiocarbamate and obtaining ethyl-4-methyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carboxylate; and (ii) desulfurizing ethyl-4-methyl-2-thioxo-2,3-dihydro-1,3-thiazole-5-carboxylate.COPYRIGHT KIPO 2017

5 - thiazole amides and biological applications

The invention relates to a 5-thiazole amide compound and biology application thereof. The 5-thiazole amide compound has a general formula (I) described in the specification and is used for targeting an AKT/PKB kinase (ATP binding site). Experiments prove that a thiazole amide AKT inhibitor can remarkably inhibit the activity of the AKT kinase in vitro and has strong proliferation inhibition function on various tumor cells with high AKT activity, which indicate that the 5-thiazole amide compound can be used for preparing drugs for resisting tumors.

Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity

Earlier we reported the discovery and design of NBD-556 and their analogs which demonstrated their potential as HIV-1 entry inhibitors. However, progress in developing these inhibitors has been stymied by their CD4-agonist properties, an unfavorable trait for use as drug. Here, we demonstrate the successful conversion of a full CD4-agonist (NBD-556) through a partial CD4-agonist (NBD-09027), to a full CD4-antagonist (NBD-11021) by structure-based modification of the critical oxalamide midregion, previously thought to be intolerant of modification. NBD-11021 showed unprecedented neutralization breath for this class of inhibitors, with pan-neutralization against a panel of 56 Env-pseudotyped HIV-1 representing diverse subtypes of clinical isolates (IC50 as low as 270 nM). The cocrystal structure of NBD-11021 complexed to a monomeric HIV-1 gp120 core revealed its detail binding characteristics. The study is expected to provide a framework for further development of NBD series as HIV-1 entry inhibitors for clinical application against AIDS.

Dual C-H activations of electron-deficient heteroarenes: Palladium-catalyzed oxidative cross coupling of thiazoles with azine N-oxides

The palladium-catalyzed, copper-promoted cross-dehydrogenative-coupling (CDC) of electron-deficient thiazoles with azine N-oxides through dual C-H activations was developed. It was found that copper(II) pivalate was an efficient dual-function reagent for the oxidative cross-coupling reactions, playing the roles of both an oxidant and a C-H bond activation promoter. This methodology provides a simple way to construct 2-thiazolyl pyridine moiety.

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.

Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK)

A series of SYK inhibitors based on the phenylamino pyrimidine thiazole lead 4 were prepared and evaluated for biological activity. Lead optimization provided compounds with nanomolar Ki's against SYK and potent inhibition in mast cell degranulation assays.

3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS

The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: wherein " G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl and indazolyl; " p is an integer ranging from 0 to 5; " R1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5, or corresponds to a group R5; " each R2 is independently hydrogen, fluorine or C1-4alkyl; " n is 2, 3, 4, or 5; " R3 is C1-4alkyl; " R4 is hydrogen, or a C1-4alkyl group, a benzyl group, a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkanoyl and SF5;or R4 is a -SR6 group; " R5 is selected from a group consisting of: isoxazolyl, -CH2-N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl and 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from a group consisting of: halogen, cyano, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy and C1-4alkanoyl; " R6 is C1-4alkyl or -CH2C3-4cycloalkyl; and when R1 is chlorine and p is 1, such R1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R1 corresponds to R5, p is 1. processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D3 receptors, e.g. to treat drug dependency, as antipsychotic agents, to treat obsessive compulsive spectrum disorders, premature ejaculation or cognition impairment.